Clinical Trial Finder | Pancreatic Cancer Action Network

Back to Trial Search

Phase I, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic Cancers

Summary

The purpose of this phase I study is to evaluate the safety and feasibility of CUE-102 in HLA-A*0201 positive patients with WT1 positive recurrent/ metastatic solid tumors, including pancreatic cancer.

General Information

NCT#: NCT05360680
Study ID: CUE-102-01
Trial Phase: Phase I

Trial Sponsor: Cue Biopharma
Therapies Used in This Trial: CUE-102

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account? Sign In

Request an Account

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account.
In order to view this information, you need to be signed in as a Health Care Provider.
In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
This information is restricted to validated Health Care Providers.

Eligibility

-------------------------------------------------------------------------------------------

In order to view this information, you need to be signed in as a Health Care Provider.
You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
------------------------------------------------------------------------------------------------------
In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information

Back to Trial Search